Merck (MRK) Provides Update on Phase 3 KEYNOTE-585 Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
| Merck & Co. (NYSE: MRK) | Delayed: 147.75 +6.82 (4.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $140.93 | 52 Week High | $65.46 | |||
| Open | $144.62 | 52 Week Low | $47.97 | |||
| Day High | $149.26 | P/E | 100.51 | |||
| Day Low | $143.32 | EPS | $1.47 | |||
| Volume | 3,966,797 | |||||
